Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2001-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00005344-200111000-00004PMID 11602814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blockade of the renin-angiotensin system.

  2002cited by this paper
• Effects of Telmisartan on Renal Excretory Function in Conscious Dogs

  2001cited by this paper
• A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.

  2000cited by this paper
• Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients

  2000cited by this paper
• Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers

  2000cited by this paper
• Compliance with antihypertensive therapy.

  1999cited by this paper
• Circadian variation in cardiovascular events.

  1999cited by this paper
• Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisited.

  1999cited by this paper
• ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

  1999cited by this paper
• THE INCIDENCE OF COUGH: A COMPARISON OF LISINOPRIL, PLACEBO AND TELMISARTAN, A NOVEL ANGIOTENSIN II ANTAGONIST

  1999cited by this paper
• Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

  1998cited by this paper
• Why ambulatory blood pressure monitoring?

  1998cited by this paper
• A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine.

  1998cited by this paper
• 佐久地域における心筋梗塞発症の Circadian Variation

  1998cited by this paper
• Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.

  1997cited by this paper
• Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues.

  1997cited by this paper
• Heart rate and the cardiovascular risk

  1997cited by this paper
• Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.

  1997cited by this paper
• Angiotensin‐II receptors: new targets for antihypertensive therapy

  1997cited by this paper
• Losartan: First of a New Class of Angiotensin Antagonists for the Management of Hypertension

  1996cited by this paper
• Bradykinin–evoked sensitization of airway sensory nerves: A mechanism for ACE–inhibitor cough

  1996cited by this paper
• ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management.

  1996cited by this paper
• Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

  1995cited by this paper
• Blockade of the renin-angiotensin system.

  1994cited by this paper
• Angiotensin‐Converting Enzyme Inhibitors and Cough: A Prospective Evaluation in Hypertension and in Congestive Heart Failure

  1994cited by this paper
• Cardioprotection with angiotensin‐converting enzyme inhibitors: Redefined for the 1990s

  1993cited by this paper
• Lack of effect of sumatriptan and UK‐14,304 on capsaicin‐induced relaxation of guinea‐pig isolated basilar artery

  1993cited by this paper
• Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

  1993influential reference
• Circadian variation in the frequency of onset of acute myocardial infarction.

  1985cited by this paper
• Does pharmacological profiling of a new drug in normotensive volunteers provide a useful guideline to antihypertensive therapy?

  1983cited by this paper

• Effects of telmisartan on metabolic syndrome components: a comprehensive review.

  2024cites this paper
• Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model

  2024cites this paper
• AT1R blocker prevents mental stress induced retrograde blood flow in overweight/obese men

  2023cites this paper
• Mental stress induces endothelial dysfunction by AT1R-mediated redox imbalance in overweight/obese men

  2023cites this paper
• АКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИ Optimization of Pharmacotherapy Within the Framework of a Patient-oriented Approach in the Treatment of Hypertension in Multimorbidity Patients (Clinical Case and Literature Review)

  2021cites this paper
• UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics—A Comprehensive Pharmacogenomic Study

  2020cites this paper
• Современные тенденции в лечении артериальной гипертонии: фокус на улучшение прогноза. Возможности фиксированной комбинации

  2020cites this paper
• How to Choose the Optimal Single-Pill Combination of the First-Line Antihypertensive Drugs? The Benefits of Amlodipine and Telmisartan Combination

  2020cites this paper
• Pharmacokinetic Interaction Between Telmisartan and Rosuvastatin/Ezetimibe After Multiple Oral Administration in Healthy Subjects

  2020cites this paper
• Current Trends in the Treatment of Hypertension: Focus on Improving Prognosis. The Capabilities of an Amlodipine/Telmisartan Single-Pill Combination

  2020cites this paper
• Angiotensin Type 1 Receptor Blockade Prevents the Decrease in Conduit Artery Flow-Mediated Dilatation during NO-synthase Inhibition in Humans

  2017influential citation
• Development of hysteresis analysis as a model-independent approach to assess temporal dissociation in pharmacokinetics and pharmacodynamics

  2016cites this paper
• Telmisartan: clinical evidence across the cardiovascular and renal disease continuum

  2016cites this paper
• Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

  2016cites this paper
• Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study.

  2016cites this paper
• Clinical Study Effect of Telmisartan on Cerebral and Systemic Haemodynamics in Patients with Recent Ischaemic Stroke : A Randomised Controlled Trial

  2015cites this paper
• Comparative effect of telmisartan vs lisinopril on blood pressure in patients of metabolic syndrome.

  2014cites this paper
• Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

  2014influential citation
• Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study.

  2014cites this paper
• A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists

  2013cites this paper
• Effect of Telmisartan on Cerebral and Systemic Haemodynamics in Patients with Recent Ischaemic Stroke: A Randomised Controlled Trial

  2013cites this paper
• Telmisartan

  2012influential citation
• Telmisartan/Hydrochlorothiazide

  2012cites this paper
• New standards in hypertension and cardiovascular risk management: focus on telmisartan

  2010cites this paper
• New standards in hypertension and cardiovascular risk management: focus on telmisartan

  2010cites this paper
• Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?

  2009cites this paper
• Development and Validation of a Reverse Phase Liquid Chromatographic Method for Quantitative Estimation of Telmisartan in Human Plasma

  2009cites this paper
• The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: A retrospective analysis of 50 studies

  2008cites this paper
• Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-&ggr;

  2008cites this paper
• Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment

  2007cites this paper
• Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients

  2007cites this paper
• Telmisartan Inhibits CD 4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor Via Peroxisome Proliferator-Activated Receptor -

  2007cites this paper
• AT1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NOS inhibition in humans.

  2007cites this paper
• Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?

  2007influential citation
• Effective treatment of hypertension by AT 1 receptor antagonism: the past and future

  2006cites this paper
• Effective treatment of hypertension by AT1 receptor antagonism: the past and future of telmisartan

  2006cites this paper
• Telmisartan/hydrochlorothiazide in the treatment of hypertension

  2006cites this paper
• Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.

  2005cites this paper
• Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension

  2005cites this paper
• Development and validation of liquid chromatography–mass spectrometry method for the determination of telmisartan in human plasma

  2005cites this paper
• Telmisartan/hydrochlorothiazide: a new fixed dose combination

  2005cites this paper
• Telmisartan: from lowering blood pressure to end-organ protection.

  2005cites this paper
• Effect of telmisartan 80 mg once daily on 24‐h blood pressure profile in patients with mild‐to‐moderate hypertension failing to respond to prior antihypertensive therapy

  2004cites this paper
• A double‐blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once‐daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild‐to‐moderate hypertension in Taiwanese patients

  2004cites this paper
• Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan.

  2004cites this paper
• Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor?

  2003cites this paper
• The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme

  2003cites this paper
• End-organ damage: does it really matter how we prevent it?

  2003cites this paper
• Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies

  2002cites this paper
• Dose Response and Safety of Telmisartan in Patients with Mild to Moderate Hypertension

  2000cites this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress New Standards in Hypertension and Cardiovascular Risk Management: Focus on Telmisartan

  year unknowncites this paper